Patients were adherent to treatment and reported low adverse event rates.

Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego.

Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home-based narrow band ultraviolet B phototherapy treatment was non-inferior to office-based phototherapy, enrolled more than 2,500 patients in the analysis. The coprimary study outcomes were physician global assessment dichotomized as 0/1 (clear/almost clear), and Dermatology Life Quality Index dichotomized as 5 or less (small to no effect on patient quality of life).

Dr. Gelfand presented data from his study group suggesting that home-based therapy was noninferior to office-based treatment, with strong P-values for noninferiority across many patient subgroups and all skin types. In fact, he said, the data suggested that home-based therapy was slightly more efficacious in the overall patient population (P<0.0001 for noninferiority).

“Not surprisingly, patients are much more adherent to treatments at home than at the office,” he noted. Adverse event rates were very low.  

“Home phototherapy is non-inferior to office phototherapy across all akin types and both primary outcomes,” said Joel Gelfand, MD, MSCE, FAAD, the James J. Leyden Professor of Dermatology and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, said in a presentation. “These data support the use of home phototherapy as a first line treatment option for psoriasis including those with no prior phototherapy experience. Efforts are clearly needed to make home office phototherapy more available to patients, as our current system has barriers like copays, insurance, or lack of coverage for these highly effective modalities.”

Source: Gelfand J. The Light Treatment Effectiveness (LITE) Study: A pragmatic trial of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis in the United States. Session S026. Presented at: American Academy of Dermatology 2024 Annual Meeting; March 8-12, 2024; San Diego.

Disclosures: Dr. Gelfand reports the following relationships: AbbVie – Consultant(Fees); Abcentra – Consultant(Fees); Amgen – Investigator(Grants/Research Funding); Artax Biopharma – Data Safety Monitoring Board(Fees); BMS – Consultant(Fees); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); CellDex – Data Safety Monitoring Board(Fees); Daavlin Company – Other(Equipment); FIDE – Consultant(Fees); GlaxoSmithKline – Consultant(Honoraria); Happify – Consultant(Fees); Healio – Other(Fees); Imagine – Data Safety Monitoring Board(Fees); Inmagene Biopharmaceuticals – Data Safety Monitoring Board(Fees); Janssen Pharmaceuticals, Inc – Consultant(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Consultant(Fees); Mindera – Consultant(Fees); Moonlake – Data Safety Monitoring Board(Fees); National Psoriasis Foundation – Investigator(Grants/Research Funding); Neumentum, Inc. – Consultant(Fees); Neuroderm LTD – Other(Fees); Novartis Pharmaceuticals Corp. – Consultant(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); UCB – Other(Fees); Veolia North America – Consultant(Fees)